Cure8 research brief
The study describes a new molecular axis (Uhrf1 → PKM2 ubiquitination) that reduced inflammation and pyroptosis in IBD models and identifies a compound (EPT) that promotes this interaction — a potential early-stage therapeutic strategy relevant to IBD research.
Researchers, translational scientists, and clinicians interested in IBD molecular mechanisms and drug discovery.
This paper used single-cell RNA sequencing, cell and mouse models (including DSS-colitis), and chemical biology to show a link between PKM2 and Uhrf1 in IBD tissues.
The authors report that EPT binds PKM2 and promotes its K48-linked ubiquitination by Uhrf1, leading to PKM2 degradation and reduced nuclear translocation; knocking down PKM2 reduced inflammation and pyroptosis in models and eliminated additional benefit from EPT in those knockdown experiments.
Findings are from preclinical experiments (single-cell RNA-seq, cell assays, and DSS mouse models) reported in the article abstract; this does not equal evidence of safety or efficacy in humans.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study describes a mechanism by which Huaier granules reduced colitis-related inflammation in mice and cell models by targeting macrophage cGAS–STING signaling and altering the gut microbiome—information that could...
Phosphatidylcholines are implicated in IBD biology; identifying a gene that regulates PC metabolism could point to new mechanistic targets. If PRKAB1 modulates epithelial lipid metabolism relevant to inflammation, it may...
This model could improve how researchers study IBD inflammation and early colorectal cancer in a human-derived, multicellular system that reproduces neuromuscular function and immune responses. That may speed preclinical...
